Bioventix Plc Director/PDMR Shareholding

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or "the Company") 
 
                               Director Dealing 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that the Company was notified on 18 October 
2021 that on the same day, Bruce Hiscock, Chief Financial Officer of the 
Company, purchased a total of 416 ordinary shares of 5 pence each in the 
Company ("Ordinary Shares"), at an average price of 3,858 pence per Ordinary 
Share (the "Purchase"). 
 
Following the Purchase, Bruce Hiscock has a beneficial interest in 416 Ordinary 
Shares, representing approximately 0.01 per cent. of the issued share capital 
of the Company. 
 
The notification below, made in accordance with the requirements of the EU 
Market Abuse Regulation, provides further details. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
This announcement contains inside information for the purposes of Article 7 of 
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law 
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed 
in accordance with the company's obligations under Article 17 of MAR. 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them 
 
1      Details of the person discharging managerial responsibilities / 
       person closely associated 
 
a)     Name                   Bruce Hiscock 
 
2.     Reason for the Notification 
 
a)     Position/status        Chief Financial Officer 
 
b)     Initial notification/  Initial notification 
       Amendment 
 
3.     Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 
a)     Name                   Bioventix Plc 
 
b)     LEI                    213800225MHX7LZQY108 
 
4.     Details of the transaction(s): section to be repeated for (i) each 
       type of instrument; (ii) each type of transaction; (iii) each date; 
       and (iv) each place where transactions have been conducted 
 
a)     Description of the     Ordinary Shares of 5 pence each 
       Financial instrument, 
       type of instrument 
 
       Identification code    GB00B4QVDF07 
 
b)     Nature of the          Purchase of Ordinary Shares 
       transaction 
 
c)     Price(s) and volume(s) Price(s)  Volume(s) 
 
                              3,855p    204 
 
                              3,861p    212 
 
d)     Aggregated 
       information: 
                              416 
       ·     Aggregated 
       volume                 3,858p 
 
       ·     Price 
 
e)     Date of the            18 October 2021 
       transaction 
 
f)     Place of the           London Stock Exchange, AIM Market (XLON) 
       transaction 
 
 
 
END

(END) Dow Jones Newswires

October 18, 2021 09:41 ET (13:41 GMT)

Bioventix (AQSE:BVXP.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024